cefprozil | cefprozil is a second-generation cephalosporin drug with broad-spectrum antibacterial effect. The bactericidal mechanism of the drug is to hinder the synthesis of bacterial cell walls. In vitro tests have proved that cefprozil has obvious effects on Staphylococcus aureus (including β-lactamase-producing strains), Streptococcus pneumoniae and Streptococcus pyogenes in gram-positive aerobic bacteria, and has inhibitory effects on Enterococcus, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus saprophytic, Warnei, Streptococcus agalactiae, Streptococcus C, D, F, G groups and Streptococcus viridans. Ineffective to methicillin-resistant Staphylococcus and Enterococcus faecalis, Haemophilus influenzae (including β-lactamase-producing strains) of gram-negative aerobic bacteria, Moraxella catarrhalis (including β-lactamase-producing strains) Highly sensitive; can inhibit Diversus Citrate, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae (including β-lactamase-producing strains), Proteus mirabilis, Salmonella, the reproduction of Shigella and Vibrio has no antibacterial effect on most strains of Acinetobacter, Enterobacter, Morgans, Proteus vulgaris, Provenia, and Pseudomonas. Cefprozil has a certain inhibitory effect on melanobacteria, Fusobacterium difficile, Perfringens, Fusobacterium, Streptococcus digestive and Propionibacterium acnes in anaerobic bacteria, and has no antibacterial effect on most fragile bacteria strains. |